Parallax Volatility Advisers’s Esperion Therapeutics ESPR Stock Holding History

Parallax Volatility Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,967	Closed	-$10.7K	–	2260
2023 Q3	$10.7K	Sell	10,967 -5,727	-34%	-$8.29K	﹤0.01%	2112
2023 Q2	$23.2K	Buy	+16,694	New	+$23.3K	﹤0.01%	2130
2022 Q1	–	Sell	-28,178	Closed	-$141K	–	3016
2021 Q4	$141K	Buy	+28,178	New	+$226K	﹤0.01%	2539
2020 Q3	–	Sell	-17,800	Closed	-$913K	–	3073
2020 Q2	$913K	Buy	+17,800	New	+$745K	﹤0.01%	1768
2019 Q3	–	Sell	-21,763	Closed	-$1.01M	–	2584
2019 Q2	$1.01M	Buy	+21,763	New	+$1.02M	﹤0.01%	1270
2019 Q1	–	Sell	-27,653	Closed	-$1.27M	–	3048
2018 Q4	$1.27M	Buy	+27,653	New	+$1.33M	﹤0.01%	1224
2018 Q3	–	Sell	-10,655	Closed	-$489K	–	2806
2018 Q2	$418K	Buy	+10,655	New	+$538K	﹤0.01%	1303
2018 Q1	–	Sell	-2,562	Closed	-$169K	–	2754
2017 Q4	$169K	Sell	2,562 -7,907	-76%	-$426K	﹤0.01%	2409
2017 Q3	$525K	Buy	10,469 +9,831	+1,541%	+$474K	﹤0.01%	1240
2017 Q2	$30K	Sell	638 -3,738	-85%	-$137K	﹤0.01%	1883
2017 Q1	$155K	Buy	+4,376	New	+$100K	﹤0.01%	2065

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Parallax Volatility Advisers's ESPR Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Esperion Therapeutics (ESPR) in Q4 2023, closing a stake of 10,967 shares — an estimated $10.7K sold.

Parallax Volatility Advisers first reported a position in ESPR in Q1 2017 and held it in 11 quarters. The position peaked at $1.27M in Q4 2018. 132 funds tracked by Wall St. Rank hold ESPR as of Q4 2023.

Parallax Volatility Advisers reported no remaining Esperion Therapeutics position as of Q4 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 10,967 Esperion Therapeutics shares in Q4 2023, an estimated $10.7K.
Parallax Volatility Advisers first reported a position in Esperion Therapeutics in Q1 2017 and held it in 11 quarters.
Parallax Volatility Advisers's Esperion Therapeutics position peaked at $1.27M in Q4 2018.
132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.